Shanghai Kaibao Pharmaceutical (300039) — Financial Flexibility Index
Shanghai Kaibao Pharmaceutical (300039) has a Financial Flexibility Index of 0.47x as of September 2025. Free cash flow of CN¥194.35 Million (operating CF CN¥190.98 Million minus capex CN¥3.37 Million) represents 0% of total liabilities (CN¥412.55 Million). Also explore Shanghai Kaibao Pharmaceutical annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai Kaibao Pharmaceutical Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Shanghai Kaibao Pharmaceutical across 19 annual periods. Check 300039 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Shanghai Kaibao Pharmaceutical (2006–2024)
Year-by-year free cash flow to debt coverage for Shanghai Kaibao Pharmaceutical. For the full company profile including market capitalisation, see Shanghai Kaibao Pharmaceutical stock valuation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.01x | CN¥419.47 Million | CN¥278.95 Million | CN¥415.45 Million | ▲ +34.1% |
| 2023 | 0.75x | CN¥411.74 Million | CN¥382.66 Million | CN¥546.82 Million | ▼ -8.1% |
| 2022 | 0.82x | CN¥408.04 Million | CN¥376.42 Million | CN¥498.24 Million | ▲ +51.0% |
| 2021 | 0.54x | CN¥168.63 Million | CN¥126.08 Million | CN¥310.90 Million | ▼ -38.7% |
| 2020 | 0.89x | CN¥264.59 Million | CN¥250.65 Million | CN¥298.96 Million | ▼ -30.9% |
| 2019 | 1.28x | CN¥349.54 Million | CN¥334.09 Million | CN¥273.01 Million | ▲ +16.4% |
| 2018 | 1.10x | CN¥288.43 Million | CN¥262.36 Million | CN¥262.26 Million | ▲ +17.2% |
| 2017 | 0.94x | CN¥295.00 Million | CN¥245.76 Million | CN¥314.26 Million | ▼ -10.1% |
| 2016 | 1.04x | CN¥341.91 Million | CN¥314.88 Million | CN¥327.61 Million | ▲ +16.4% |
| 2015 | 0.90x | CN¥377.48 Million | CN¥327.08 Million | CN¥421.16 Million | ▼ -40.6% |
| 2014 | 1.51x | CN¥351.12 Million | CN¥282.38 Million | CN¥232.72 Million | ▼ -36.0% |
| 2013 | 2.36x | CN¥388.52 Million | CN¥270.23 Million | CN¥164.72 Million | ▲ +13.6% |
| 2012 | 2.08x | CN¥295.53 Million | CN¥243.32 Million | CN¥142.29 Million | ▲ +46.6% |
| 2011 | 1.42x | CN¥167.16 Million | CN¥98.31 Million | CN¥117.97 Million | ▲ +167.0% |
| 2010 | 0.53x | CN¥70.80 Million | CN¥19.79 Million | CN¥133.39 Million | ▼ -40.8% |
| 2009 | 0.90x | CN¥178.44 Million | CN¥52.74 Million | CN¥199.20 Million | ▲ +207.6% |
| 2008 | 0.29x | CN¥29.98 Million | CN¥18.70 Million | CN¥102.95 Million | ▼ -11.6% |
| 2007 | 0.33x | CN¥27.89 Million | CN¥23.27 Million | CN¥84.64 Million | ▼ -24.7% |
| 2006 | 0.44x | CN¥31.43 Million | CN¥19.70 Million | CN¥71.80 Million | — |